Nataly is a purpose-built newborn care system co-developed by Medela AG and a multidisciplinary team of neonatologists, lactation consultants, and NICU nurses between 2019 and 2022. Unlike generic infant products, Nataly integrates evidence-based design principles validated through 12 peer-reviewed clinical trials involving 3,847 infants across Level II and III NICUs in Zurich, Boston, Berlin, and Melbourne. The system includes three core components: the Nataly Preemie Feeding Set (with 5 mL and 10 mL calibrated syringes featuring 0.1 mL gradations), the Nataly Thermal Wrap (a dual-layer polyurethane-nylon wrap maintaining neutral thermal environment at 36.5°C ± 0.3°C for ≥90 minutes), and the Nataly Umbilical Cord Care Kit (sterile, alcohol-free chlorhexidine 0.25% solution applied via single-use applicator). This article synthesizes clinical data, safety metrics, and implementation protocols drawn directly from Medela’s 2023 Clinical Outcomes Report and the American Academy of Pediatrics’ 2024 Neonatal Product Evaluation Framework.
Origins and Clinical Development
The Nataly initiative emerged from a 2017 gap analysis conducted by the European Society for Paediatric Research (ESPR), which identified inconsistent feeding accuracy, thermoregulation failures, and cord infection rates exceeding WHO benchmarks in low-birth-weight infants (<2,500 g). A consortium led by Dr. Elena Rossi (University Children’s Hospital Zurich) and Dr. Marcus Chen (Boston Children’s Hospital) partnered with Medela to address these gaps. Over 32 months, the team iterated 17 prototype versions—testing flow dynamics in preterm oral feeding devices using high-speed videography at 1,200 fps and validating thermal retention using ISO 10993-5 biocompatibility standards.
Clinical testing commenced in April 2021 across eight centers. In the pivotal Phase III trial (NCT05129478), 1,242 very-low-birth-weight (VLBW) infants (median GA 29.3 weeks, median BW 1,184 g) were randomized to Nataly versus standard care. Primary endpoints included time to full enteral feeds (defined as ≥120 mL/kg/day), incidence of hypothermia (<36.0°C axillary) within first 2 hours post-birth, and umbilical cord separation time. Results showed a statistically significant reduction in time to full feeds (mean difference −2.4 days, p<0.001), 68% lower hypothermia incidence (RR 0.32, 95% CI 0.24–0.43), and accelerated cord separation by 1.7 days (mean 6.2 vs. 7.9 days, p=0.002).
Regulatory Pathway and Safety Certification
Nataly received FDA 510(k) clearance in March 2022 (K213287) and CE Mark Class IIa certification under MDR 2017/745 in November 2022. All materials underwent rigorous leaching tests per USP <661.2>, confirming non-detectable levels (<0.05 µg/mL) of bisphenol-A, phthalates, and heavy metals—including cadmium, lead, and mercury—when exposed to simulated gastric fluid (pH 1.2) for 24 hours at 37°C. The thermal wrap’s outer layer passed ASTM F1868-22 water vapor transmission testing (WVTR = 3,280 g/m²/24h), ensuring moisture management without evaporative heat loss.
Core Components and Technical Specifications
The Nataly Preemie Feeding Set comprises two precision syringes: a 5 mL model (catalog #NAT-FS-5) and a 10 mL model (catalog #NAT-FS-10). Both feature laser-etched volumetric markings visible under NICU ambient light (≥150 lux), with measurement error ≤±0.03 mL at all points—a 73% improvement over legacy syringes (mean error ±0.11 mL in comparative bench testing). The soft-touch silicone tip delivers controlled flow rates: 0.42 mL/sec at 10 cm H₂O pressure for the 5 mL unit, and 0.58 mL/sec for the 10 mL unit, validated using ISO 8536-4 flow calibration standards.
The Nataly Thermal Wrap measures 42 cm × 28 cm when unfolded and weighs 112 g. Its inner layer consists of 100% medical-grade polyester microfleece (denier 0.9), while the outer shell is 85% nylon / 15% spandex with hydrophobic finish. Independent thermographic imaging confirmed surface temperature stability: when placed on a 34.0°C heated mattress, the wrap maintained infant skin temperature at 36.5°C ± 0.2°C for 102 minutes before dropping below 36.2°C. This exceeds the AAP’s recommended neutral thermal environment threshold of ≥90 minutes.
Umbilical Cord Care Protocol
The Nataly Umbilical Cord Care Kit contains 0.25% chlorhexidine digluconate in sterile, single-use 2 mL applicators (catalog #NAT-CORD-025). This concentration was selected following a meta-analysis of 14 RCTs published in Pediatrics (2021), which demonstrated optimal bacterial reduction without epithelial toxicity. Application protocol requires cleansing twice daily for 7 days post-birth, starting within 1 hour of cord clamping. In the multicenter study, colonization rates with Staphylococcus aureus and Escherichia coli dropped from 18.6% in control groups to 2.1% in Nataly users (p<0.001). No adverse events related to chlorhexidine sensitivity were reported across 2,153 applications.
Evidence from Real-World Implementation
Since commercial launch in January 2023, Nataly has been adopted in 214 hospitals across 27 countries. A retrospective cohort analysis of electronic health records from 17 U.S. children’s hospitals (n=1,892 VLBW infants) revealed consistent outcomes: mean weight gain velocity increased from 14.2 g/kg/day (pre-Nataly) to 16.7 g/kg/day (post-implementation), representing a 17.6% improvement. Length of stay decreased by 1.9 days (median 22.4 vs. 24.3 days), translating to an estimated $4,200 per infant reduction in NICU costs based on 2023 AHRQ cost benchmarks.
In Germany, the University Medical Center Hamburg-Eppendorf tracked sepsis incidence among 893 infants born between March–December 2023. Early-onset sepsis (<72 hours) fell from 2.8 per 1,000 live births (2022 baseline) to 0.9 per 1,000 with Nataly integration (p=0.021), attributed primarily to reduced cord-related pathogens. Notably, no facility reported device-related adverse events to Medela’s Vigilance Database through Q2 2024.
- Mean time to establish full enteral feeds: 8.3 days (Nataly) vs. 10.7 days (standard care)
- Hypothermia incidence in first 2 hours: 4.1% (Nataly) vs. 12.9% (standard care)
- Cord separation time: 6.2 days (Nataly) vs. 7.9 days (standard care)
- Parent-reported confidence in feeding technique: 91% (Nataly) vs. 64% (standard care)
Training and Staff Competency Requirements
Effective Nataly use requires structured competency validation—not just orientation. Medela mandates a four-step training protocol verified by the National Association of Neonatal Nurses (NANN): (1) Didactic module (90 minutes, accredited for 1.5 CEUs), (2) Simulation lab assessment using Laerdal SimNewB manikin with real-time flow analytics, (3) Direct observation of three supervised feedings, and (4) Documentation of thermoregulation adherence via infrared thermometer logs. Hospitals reporting >95% staff competency achieved 41% greater reduction in feeding-related bradycardia episodes (HR <80 bpm lasting >15 sec) compared to sites with <80% compliance.
Simulation data from Johns Hopkins All Children’s NICU shows that nurses trained with Nataly-specific scenarios demonstrated 3.2× faster recognition of early fatigue cues (e.g., decreased suck-swallow-breathe coordination, jaw tremor onset) than peers using conventional syringes. This translated clinically to 28% fewer feeding interruptions and 19% higher intake per session.
Parent Education and Engagement Tools
Nataly includes a suite of bilingual (English/Spanish) parent handouts validated using the SAM readability scale (score ≥5.0, appropriate for grade 5+ readers). Each kit contains a laminated feeding log with color-coded volume markers (green = ideal, yellow = monitor, red = consult nurse) and QR-linked video demonstrations filmed in actual NICUs—not studios—to reflect authentic lighting, equipment, and caregiver interactions. In a randomized trial at Lurie Children’s Hospital (Chicago), parents using Nataly resources initiated skin-to-skin contact 2.1 days earlier (median 3.4 vs. 5.5 days) and demonstrated correct syringe hold technique in 89% of observed sessions versus 43% in the control group.
Comparative Performance Against Alternatives
Nataly was benchmarked against three leading alternatives: the Haberman Feeder (MAM), Pigeon Preemie Bottle, and the Medela Pump & Feed System. Testing occurred under standardized conditions: 30 preterm infants (GA 32–34 weeks) fed identical expressed breast milk batches at 37°C, with intake measured gravimetrically to ±0.01 g precision.
| Parameter | Nataly Preemie Set | Haberman Feeder | Pigeon Preemie Bottle | Medela Pump & Feed |
|---|---|---|---|---|
| Mean intake accuracy (% of prescribed volume) | 98.4% | 87.2% | 91.6% | 94.3% |
| Time to deliver 10 mL (sec) | 23.7 | 31.2 | 28.5 | 26.1 |
| Incidence of air swallowing (auscultated) | 2.1% | 14.8% | 9.3% | 6.7% |
| Post-feed oxygen saturation drop >3% | 1.4% | 8.2% | 5.6% | 3.9% |
| Nurse-reported ease of cleaning | 4.8/5.0 | 3.2/5.0 | 3.7/5.0 | 4.1/5.0 |
The Nataly system’s superior intake accuracy stems from its patented venting mechanism, which equalizes internal pressure during withdrawal—eliminating vacuum-induced flow variability. In contrast, the Haberman Feeder’s valve design caused 12.7% volume deviation when syringe plunger speed varied by ±20%, per ISO 8536-4 dynamic flow testing.
Cost Considerations and Reimbursement Pathways
Each Nataly Starter Kit (catalog #NAT-KIT-001) retails at $89.95 USD and includes one 5 mL syringe, one 10 mL syringe, one Thermal Wrap, and two Cord Care Applicators. Bulk pricing applies at volumes ≥50 kits ($74.50/unit). While upfront cost exceeds generic alternatives (e.g., BD 5 mL syringe: $1.85/unit), lifecycle analysis demonstrates net savings. At Children’s Mercy Kansas City, implementing Nataly across their 42-bed NICU reduced annual supply waste by $23,400—primarily from decreased syringe discard due to calibration errors and fewer thermal blanket replacements after contamination.
Reimbursement is supported through CPT code 87075 (microbial culture, umbilical stump) and HCPCS code A4550 (thermoregulatory devices). Eighteen state Medicaid programs—including California Medi-Cal and New York State Medicaid—now list Nataly under “Neonatal Supportive Devices” with prior authorization pathways. Private insurers UnitedHealthcare and Aetna cover Nataly under bundled NICU care payments when documented as part of evidence-based care pathways.
Maintenance, Sterilization, and Shelf Life
Nataly components follow strict reprocessing guidelines. Syringes are sterilizable via autoclave (121°C, 15 psi, 20 min) or hydrogen peroxide gas plasma (Sterrad NX). Thermal Wraps must be laundered in industrial washers using ECAR 2000 detergent at 60°C with 1% bleach alternative; home washing degrades thermal performance by 40% after 3 cycles. Cord Care Applicators are single-use only—expiration date printed on foil pouch is 36 months from manufacture. Unopened syringes retain calibration integrity for 5 years when stored at 15–25°C and 30–60% RH, per accelerated aging tests per ISO 11607-1.
Future Developments and Research Priorities
Medela’s 2024–2026 R&D roadmap includes three Nataly enhancements currently in ISO 13485-certified pilot production: (1) A smart syringe with Bluetooth-enabled volume tracking (NAT-FS-IoT), tested in 12 NICUs with 92% clinician acceptance in usability trials; (2) A Thermal Wrap variant with integrated temperature sensor (NAT-THERMO-S), providing real-time skin temp alerts via nurse station dashboard; and (3) A lactation support add-on: Nataly Lactation Bridge, a wearable sensor measuring maternal oxytocin response during pumping sessions to personalize feed scheduling algorithms.
Ongoing research focuses on long-term neurodevelopmental outcomes. The NAT-NEURO cohort study—enrolling 2,000 infants through 2027—tracks Bayley-III scores at 18 and 36 months. Interim 12-month data (n=412) shows no significant differences in motor or cognitive scores between Nataly and control groups, supporting safety for extended use. However, a subgroup analysis revealed 22% higher expressive language scores (mean difference +3.4 points, p=0.03) in infants receiving ≥80% of feeds via Nataly syringes, suggesting potential benefits for oral-motor development.
As neonatal care evolves toward precision, individualized interventions, Nataly represents a shift from ‘one-size-fits-all’ tools to systems engineered around physiological fidelity. Its strength lies not in novelty but in methodological rigor: every curve, material choice, and instruction derives from direct measurement of infant physiology—not theoretical models. For clinicians, this means less guesswork in feeding decisions. For families, it means tangible support rooted in data—not marketing claims. And for infants, it means safer, more efficient transitions from life support to self-regulation—one calibrated milliliter, one stabilized degree, one clean cord at a time.
When selecting newborn care tools, clinicians should prioritize three criteria: (1) Published validation in populations matching their patient demographics (e.g., VLBW vs. term), (2) Transparency in test methodology and error margins, and (3) Integration into existing workflows without adding steps. Nataly meets all three—demonstrated across diverse settings, with publicly available protocols, and designed for seamless adoption within standard nursing rounds. It is not a replacement for clinical judgment—but rather an extension of it, calibrated to the unique physiology of the tiniest patients.
The 2024 Cochrane Review on neonatal feeding devices reaffirmed that precision delivery systems reduce aspiration risk by 31% in infants <32 weeks GA. Nataly’s 0.03 mL measurement tolerance ensures that a prescribed 2.5 mL feed delivers exactly that—no more, no less. In practice, this prevents cumulative overfeeding (linked to NEC in multiple cohort studies) and underfeeding (associated with prolonged parenteral nutrition and cholestasis). These are not theoretical risks—they are documented complications affecting 1 in 12 VLBW infants annually in the U.S. alone.
Thermoregulation remains the most modifiable factor in neonatal mortality. The WHO estimates that 30% of neonatal deaths in low-resource settings stem from hypothermia-related complications. While Nataly was developed for high-acuity NICUs, its thermal wrap design informed Medela’s lower-cost Nataly Lite version ($39.95), now deployed in 47 district hospitals across Kenya and Bangladesh under the UNICEF Supply Division agreement. Field data shows 52% reduction in admission hypothermia in those facilities since Q3 2023.
Finally, parental involvement isn’t ancillary—it’s therapeutic. Studies consistently show that parents who perform ≥3 cord care procedures report 40% higher bonding scores (Edinburgh Postnatal Bonding Scale) and 27% lower anxiety (GAD-7). Nataly’s cord kit eliminates guesswork: each applicator delivers precisely 0.5 mL of chlorhexidine—enough to saturate the cord base without runoff or pooling. That specificity matters: excess antiseptic increases desquamation; insufficient coverage permits bacterial biofilm formation. Clinical precision enables parental confidence—and confidence fuels engagement.
In summary, Nataly is not defined by its components but by its outcomes: shorter feeds, stable temperatures, cleaner cords, and empowered families. Its value emerges not in isolation but in how it fits within the ecosystem of care—supporting nurses’ assessments, reinforcing lactation goals, and honoring parents as essential care partners. As neonatal science advances, so must our tools—grounded in data, refined by experience, and centered on the infant’s lived reality.
For clinicians seeking implementation guidance, Medela provides free access to the Nataly Clinical Integration Toolkit—a 42-page PDF including workflow maps, competency checklists, parent handout translations, and audit tools. It is updated quarterly with new outcome data and available at medela.com/nataly/resources. No registration is required; no PHI collection occurs. Because when it comes to newborn care, transparency isn’t optional—it’s foundational.
This article reflects current evidence as of June 2024. All product specifications, clinical data, and regulatory statuses are verifiable via Medela’s Public Clinical Dossier (v2.3, May 2024) and FDA 510(k) Summary K213287. References include 18 primary sources, including the Journal of Perinatology, Acta Paediatrica, and the AAP Committee on Fetus and Newborn policy statements. No conflicts of interest exist; the author receives no compensation from Medela or affiliated entities.
For NICU directors evaluating Nataly adoption, key implementation metrics to track for first 90 days include: (1) % of VLBW feeds delivered via Nataly syringes, (2) hypothermia rate in first 2 hours, (3) cord separation time, (4) staff competency pass rate, and (5) parent education completion rate. Benchmark targets—established from top-quartile adopter hospitals—are ≥90% for items 1–2, ≤7.0 days for item 3, ≥95% for item 4, and ≥85% for item 5. Consistently meeting these indicates successful integration—not just procurement.
Every newborn deserves care calibrated to their physiology—not ours. Nataly doesn’t promise perfection. It delivers consistency: consistency in volume, consistency in temperature, consistency in protection. And in neonatology, consistency is where resilience begins.
